October 12, 2021





Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, NE

Washington, DC 20549

Attention: Michael Davis



DiaMedica Therapeutics Inc.


Registration Statement on Form S-3


Filed October 5, 2021


File No. 333-260066


Request for Acceleration


Ladies and Gentlemen:


Pursuant to Rule 461 of the Securities Act of 1933, as amended, DiaMedica Therapeutics Inc. (the “Registrant”) hereby respectfully requests that the effective date of the above-referenced registration statement be accelerated so that it will be declared effective at 5:00 p.m., Eastern Time, on October 14, 2021, or as soon thereafter as is practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Fox Rothschild LLP, counsel to the Registrant, to orally modify or withdraw this request for acceleration.


The Registrant requests that it be notified of such effectiveness by a telephone call to Amy Culbert of Fox Rothschild LLP at (612) 607-7287.


Thank you for your assistance in this matter. Should you have any questions, please call Ms. Culbert.


Very truly yours,


/s/ Rick Pauls


Rick Pauls

President and Chief Executive Officer